Emeline M Van Craenenbroeck
Overview
Explore the profile of Emeline M Van Craenenbroeck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
134
Citations
2041
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boen H, Pype L, Papadimitriou K, Altintas S, Teuwen L, Anguille S, et al.
Cardiooncology
. 2025 Mar;
11(1):27.
PMID: 40087712
Background: SERPINA3 recently emerged as potential prognostic biomarker in heart failure. In a population of cancer survivors with cancer therapy-related cardiac dysfunction (CTRCD) circulating SERPINA3 was elevated compared to age-matched...
2.
Dinges S, Schwedhelm E, Schoenfeld J, Gevaert A, Winzer E, Haller B, et al.
Eur J Prev Cardiol
. 2025 Mar;
PMID: 40083304
Aims: Exercise has been shown to affect the nitric oxide (NO) pathway, which is involved in the pathophysiology of endothelial dysfunction in heart failure (HF) with reduced (HFrEF) and preserved...
3.
Vanreusel I, Hens W, Van Craenenbroeck E, Paelinck B, Segers V, Van Berendoncks A
Cardiol Young
. 2025 Mar;
:1-8.
PMID: 40064557
Introduction: Vitamin D is crucial for normal organ function, vascular health and exercise performance, yet its deficiency is widespread. Patients with CHD often exhibit reduced exercise capacity. Limited research exists...
4.
Verelst F, Van Assche L, Huybrechts W, Gevaert A, Van Craenenbroeck E
Eur Heart J Case Rep
. 2025 Feb;
9(1):ytae687.
PMID: 40007991
Background: Cardiac contractility modulation (CCM) is a novel device-based therapeutic option in patients with heart failure with reduced ejection fraction who are not eligible for cardiac resynchronization therapy. Cardiac contractility...
5.
Van Asbroeck B, Kruger D, Van den Bogaert S, Dombrecht D, Bosman M, Van Craenenbroeck E, et al.
Int J Mol Sci
. 2025 Feb;
26(3).
PMID: 39940943
The chemotherapeutic agent doxorubicin (DOX) leads to the loss of skeletal muscle and adipose tissue mass, contributing to cancer cachexia. Experimental research on the molecular mechanisms of long-term DOX treatment...
6.
Gevaert A, Winzer E, Mueller S, De Schutter S, Beckers P, Hommel J, et al.
ESC Heart Fail
. 2025 Feb;
PMID: 39936502
Aims: Exercise training improves aerobic capacity (V̇Opeak) in patients with heart failure and preserved ejection fraction (HFpEF), but underlying mechanisms remain unclear. We aimed to evaluate whether exercise training could...
7.
De Schutter S, Van Damme E, Van Hout G, Pype L, Gevaert A, Van Craenenbroeck E, et al.
Am J Cardiol
. 2025 Jan;
240:57-63.
PMID: 39800180
Atrial functional mitral regurgitation (AFMR) is a distinct form of mitral regurgitation in patients with atrial fibrillation and heart failure with preserved ejection fraction. Its pathophysiology remains elusive, and data...
8.
Vrints C, Andreotti F, Koskinas K, Rossello X, Adamo M, Ainslie J, et al.
G Ital Cardiol (Rome)
. 2024 Nov;
25(12 Suppl 1):e1-e132.
PMID: 39611224
No abstract available.
9.
van Eijgen J, Van Winckel L, Hanssen H, Kotliar K, Vanassche T, Van Craenenbroeck E, et al.
Surv Ophthalmol
. 2024 Nov;
70(2):200-214.
PMID: 39592075
The retina allows noninvasive in vivo assessment of the microcirculation. Autoregulation of the retinal microvasculature meets the changing requirements of local metabolic demand and maintains adequate blood flow. Analysis of...
10.
Kruger D, Bosman M, Van Craenenbroeck E, De Meyer G, Franssen C, Guns P
Cardiooncology
. 2024 Oct;
10(1):65.
PMID: 39367508
Background: Doxorubicin (DOX) is used for breast cancer and lymphoma, but can cause cardiotoxicity, arterial stiffness, and endothelial dysfunction. We recently reported SERPINA3N as biomarker of cardiovascular toxicity in patients...